TG Therapeutics' stock rose after Q4 2023 revenues exceeded expectations, with Briumvi U.S. net product revenue at $39.9M and European Commission approval.

TG Therapeutics' stock increased after reporting Q4 2023 revenues of $43.97M, exceeding the consensus of $40.06M. Briumvi U.S. net product revenue reached $39.9M for Q4 2023, with 3,200 prescriptions received since launch. The European Commission approved Briumvi, leading to a partnership with Neuraxpharm for ex-U.S. commercialization. TG Therapeutics' stock has experienced multiple buy ratings and target price increases from analysts.